The second newsletter of ProCAncer-I has been published!

An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum: In Europe, prostate cancer (PC) is the second most frequent type of cancer in men and the third most lethal. Current clinical practices lead to overdiagnosis and overtreatment, necessitating more effective tools for discriminating between aggressive and non-aggressive disease. The EU-funded ProCAncer-I project proposes to develop advanced artificial intelligence models to address unmet clinical needs: diagnosis, metastases detection and prediction of response to treatment. To achieve this, partners will generate a large interoperable repository of health images, and a scalable high-performance computing platform hosting the largest collection of PC Magnetic Resonance Images used for developing robust PC AI models. To ensure the rapid clinical implementation of the models developed, the project’s partners will robustly monitor performance, accuracy and reproducibility. 

Welcome by Coordinating Team

We are very glad to lead a very ambitious and health-driven project that could end to alleviating and helping thousands of men to tackle prostate cancer in a more personalized way supporting a better quality of life

The Coordinating Team

Manolis Tsiknakis

Prof. Manolis Tsiknakis
(Coordinator)

Dr. Nickolaos Papanickolaou
(Scientific Manager)

Prof. Kostas Marias
(Technical Manager)

Prof. Daniele Regge
(Clinical Manager)

The ProCAncer-I project is one of the founding projects of the FUTURE-AI.

FUTURE-AI is an international, multi-stakeholder initiative for defining and maintaining concrete guidelines that will facilitate the design, development, validation, and deployment of trustworthy AI solutions in medical imaging based on six guiding principles: Fairness, Universality, Traceability, Usability, Robustness, and Explainability.

Project Information

Months (Duration)

Euros (Total Budget )

Grant Agreement Nr.

Funded

This project has received funding from the European Union’s Horizon 2020 research and innovation programme

|

Topic

DT-TDS-05-2020:
AI for Health Imaging

Highlights

Our project coordinator, Gianna Tsakou, presented the common challenges that an EU cancer imaging infrastructure brings in a webinar organized by the @EU_Commission for the #eHealth Stakeholder Group 👇 https://incisive-project.eu/new/what-are-the-opportunities-and-challenges-of-a-common-approach-towards-an-eu-cancer-imaging-infrastructure/

📣 Our second winter #Newsletter has been released! Check out the latest developments and recent news 👉 https://bit.ly/3fGBUrc
📧 Do not forget to subscribe for our next editions!
.
.
.
#HorizonEU #H2020 #AI #health_imaging #EUfunded #prostatecancer #EU_HEALTH

Meet the team!
The Biomedical Imaging Research group @GIBI230, as part of @IISLaFe, is a reference center in the Development and Validation of Imaging Biomarkers with #Artificial_Intelligence.
#HorizonEU #H2020 #EUfunded #prostatecancer #Cancer #cancerdetection #EU_HEALTH

👏New publication👏from the research groups in Pisa and Valencia, in the framework of the collaboration between the #AI for health imaging #EU_funded projects!
➡️https://link.springer.com/article/10.1007%2Fs00330-021-08431-6
@chaimeleon_eu @primage @EuCanImage @ProCAncer_I @EU_Health

PSMA PET/CT better detects prostate cancer spread, long-term outcomes over conventional imaging https://www.healthimaging.com/topics/molecular/psma-petct-prostate-cancer-outcomes

Load More...

Stay in touch!